Carmell Corporation

CTCX

US1429221039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.49 ^USD	+1.63%		-3.11%	-34.65%

May. 15	Carmell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 11	Carmell Corporation announced that it has received $3 million in funding	CI

Carmell Therapeutics Corporation(NasdaqCM:CTCX) added to S&P TMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Carmell Corporation

Carmell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Carmell Corporation announced that it has received $3 million in funding	Apr. 10	CI
Carmell Corporation announced that it expects to receive $3 million in funding	Apr. 03	CI
Carmell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
An undisclosed buyer completed the acquisition of Axolotl Biologix, Inc. from Carmell Corporation.	Mar. 25	CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Fed Maintains Rate Cut Outlook	Mar. 21	MT
Carmell Sells Axolotl Biologix Unit -- Shares Jump Premarket	Mar. 21	MT
An undisclosed buyer entered into a a definitive agreement to acquire Axolotl Biologix, Inc. from Carmell Corporation ).	Mar. 19	CI
Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024	Feb. 26	CI
Carmell Corporation Announces Appointment of Dr. Bradley Calobrace to Scientific Advisory Board	Jan. 17	CI
Carmell Corp Announces Appointment of Dr. Jason D. Bloom to Scientific Advisory Board	Jan. 17	CI
Carmell Corporation Announces Appointment of Dr. Adam Rubinstein to Scientific Advisory Board	Jan. 17	CI
Carmell Corporation Announces Appointment of Dr. Gregory A. Buford to Scientific Advisory Board	Jan. 17	CI
Carmell Corporation Announces Appointment of Dr. Sean Kelishadi to Scientific Advisory Board	Jan. 17	CI
Carmell Corporation Announces Addition of Two Independent Directors	Nov. 16	CI
Carmell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Carmell Therapeutics Corporation(NasdaqCM:CTCX) added to S&P TMI Index	23-09-18	CI
Carmell Corporation Announces Board Changes	23-09-06	CI
Carmell Corporation Announces CEO Changes	23-09-06	CI
Carmell Closes Axolotl Biologix Merger	23-08-09	MT
Carmell Therapeutics Corporation completed the acquisition of Axolotl Biologix, Inc.	23-08-08	CI
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading	23-07-28	MT
Strong GDP Growth, Meta Platforms' Earnings Fuel Premarket Gains for US Equity Futures	23-07-27	MT
Top Premarket Gainers	23-07-27	MT
Carmell Therapeutics Corporation entered into a definitive agreement to acquire Axolotl Biologix, Inc.	23-07-26	CI

Carmell Corporation (Carmell) is a bio-aesthetics company focused on skin and hair health. The Company utilizes the Carmell Secretome to support skin and hair health. The Carmell Secretome consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from United States Food and Drug Administration-approved tissue banks. The Company has developed a novel micellar nanoparticle formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the harmful excipients that are used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Additionally, Carmellâs micellar formulations do not utilize mineral or vegetable oils across their entire product line and are designed to be non-comedogenic. The Company is also developing a line of menâs products and a line of topical haircare products.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CARMELL CORPORATION	-34.65%	67.07M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B